Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study - Top-Institutions - MDSpire

Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study

  • By

  • Xin Wan

  • Dechuan Liu

  • Haotian Wang

  • Wei Guo

  • Xingtong Wang

  • Yangzhi Zhao

  • Ou Bai

  • June 18, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    First Hospital of Jilin University
    First Hospital of Jilin University

    Changchun, Jilin

    Key Differentiators

    • Hematology

  • #2

    University of British Columbia
    University of British Columbia

    Vancouver, British Columbia

    Key Differentiators

    • Hematology

  • #3

    British Columbia Cancer Center Agency, Center for Lymphoid Cancer
    British Columbia Cancer Center Agency, Center for Lymphoid Cancer

    Vancouver, British Columbia

    Key Differentiators

    • Hematology

  • #4

    German CLL Group
    German CLL Group

    Germany

    Key Differentiators

    • Hematology

  • #5

    University Hospital Cologne
    University Hospital Cologne

    Cologne, North Rhine-Westphalia

    Key Differentiators

    • Hematology

Original Source(s)

Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study

  • by Xin Wan, Dechuan Liu, Haotian Wang, Wei Guo, Xingtong Wang, Yangzhi Zhao, Ou Bai

  • June 18, 2026

Related Content

A Case Report of follicular dendritic cell sarcoma

Machine learning-driven identification and immunohistochemical validation of an integrated immune-inflammatory phenotype for disease-free survival stratification in breast cancer

Transcriptome-Inferred metabolic subtypes define prognostic and immune ecosystems in osteosarcoma at single-cell resolution